BioSpace News Archive

Just over half of consumers across the EU5 markets reported asking their doctor for a specific medication in the past 12 months – and half of these patients said they were always prescribed the requested drug.

OM1, a leading health outcomes and technology company, today announced the publication of new harmonized outcome measures for atrial fibrillation (AF) in HeartRhythm.

Company Integrates Latest Acquisition and Builds Corporate Foundation for Growth

Relatient today announced it ranked 190 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America.

The U.S. patents issued range in subject matter and include coverage of the Axonics clinician programmer, patient remote control, and internal system electronics.

Pulmatrix. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present the results of the recently completed phase 1/1b clinical trial of Pulmazole, an inhaled dry-powder iSPERSE™ formulation of itraconazole, at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology in Seattle, Washington on November 17, 2018.

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, demonstrated proof-of-mechanism at tolerable doses in patients with advanced solid tumors.

FUJIFILM Medical Systems U.S.A.,Inc. will showcase its complete line of innovative Enterprise Imaging and Informatics solutions at the Radiological Society of North America’s (RSNA) annual meeting to be held from November 25-30, 2018 at McCormick Place in Chicago, IL.

Company sponsors two symposiums; awards research grants; exhibits comprehensive imaging and healthcare IT portfolio

This pre-clinical immuno-oncology research will utilize PsiOxus’ proprietary T-SIGn platform.